World Library  
Flag as Inappropriate
Email this Article

Oxiracetam

Article Id: WHEBN0000947935
Reproduction Date:

Title: Oxiracetam  
Author: World Heritage Encyclopedia
Language: English
Subject: Piracetam, Racetam, Ampakine, Racetams, PEPA (drug)
Collection: Acetamides, Alcohols, Ampa Receptor Agonists, Pyrrolidones, Racetams, Stimulants
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Oxiracetam

Oxiracetam
Systematic (IUPAC) name
(RS)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide
Clinical data
Legal status
  • Unscheduled (US)
Routes of
administration
Oral
Pharmacokinetic data
Biological half-life 8 hours
Identifiers
CAS Registry Number  N
ATC code N06
PubChem CID:
ChemSpider  Y
UNII  Y
KEGG  Y
ChEMBL  Y
Chemical data
Formula C6H10N2O3
Molecular mass 158.155
 N   

Oxiracetam (ISF 2522) is a nootropic drug of the racetam family and very mild stimulant.[1][2] Several studies suggest that the substance is safe even when high doses are consumed for a long period of time.[3][4][5] However, the mechanism of action of the racetam drug family is still a matter of research. Oxiracetam is not approved by Food and Drug Administration for any medical use in the United States.

Contents

  • Clinical findings 1
  • Pharmacokinetics 2
  • See also 3
  • References 4
  • External links 5

Clinical findings

There has been effort put into investigating the possible use of oxiracetam as a medication to attenuate the symptoms of dementia.[6] However, no convincing results were obtained from studies where patients suffering from

  • US National Library of Medicine

External links

  1. ^ Malykh, A. G.; Sadaie, M. R. (2010). "Piracetam and Piracetam-Like Drugs". Drugs 70 (3): 287–312.  
  2. ^ Valzelli, L.; Baiguerra, G.; Giraud, O. (1986). "Difference in learning and retention by Albino Swiss mice. Part III. Effect of some brain stimulants". Methods and findings in experimental and clinical pharmacology 8 (6): 337–341.  
  3. ^ Parnetti, L; Mecocci, P; Petrini, A; Longo, A; Buccolieri, A; Senin, U (1989). "Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group". Neuropsychobiology 22 (2): 97–100.  
  4. ^ Itil, T. M.; Menon, G. N.; Songar, A; Itil, K. Z. (1986). "CNS pharmacology and clinical therapeutic effects of oxiracetam". Clinical neuropharmacology. 9 Suppl 3: S70–2.  
  5. ^ Perucca, E; Parini, J; Albrici, A; Visconti, M; Ferrero, E (1987). "Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly". European journal of drug metabolism and pharmacokinetics 12 (2): 145–8.  
  6. ^ a b c d e f Gouliaev, A. H.; Senning, A. (1994). "Piracetam and other structurally related nootropics". Brain Research Reviews 19 (2): 180–222.  
  7. ^ Fordyce DE, Clark VJ, Paylor R, Wehner JM (February 1995). "Enhancement of hippocampally-mediated learning and protein kinase C activity by oxiracetam in learning impaired DBA/2 mice". PubMed. 
  8. ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 10th edition, Biomedical Publications, Seal Beach, CA, 2014, p. 1524-1525.

References

See also

Oxiracetam is well absorbed from the gastrointestinal tract with a bioavailability of 56-82%.[6] Peak serum levels are reached within one to three hours after a single 800 mg or 2000 mg oral dose, with the maximal serum concentration reaching between 19-31 µg/ml at these doses. Oxiracetam is mainly cleared renally and approximately 84% is excreted unchanged in the urine. The half-life of oxiracetam in healthy individuals is about 8 hours, whereas it is 10–68 hours in patients with renal impairment. There is some penetration of the blood–brain barrier with brain concentrations reaching 5.3% of those in the blood (measured one hour after a single 2000 mg intravenous dose).[6] Clearance rates range from 9 to 95 ml/min and steady-state concentrations when 800 mg is given twice daily range from 60 µM to 530 µM. The highest brain concentrations of oxiracetam are found in the septum pellucidum, followed by the hippocampus, the cerebral cortex and with the lowest concentrations in the striatum after a 200 mg/kg oral dose given to rats.[6] Oxiracetam may be quantitated in plasma, serum or urine by liquid chromatography with one of several different detection techniques.[8]

Pharmacokinetics

Research shows oxiracetam improves hippocampally-mediated learning performance by increasing membrane-bound protein kinase C (PKC). When compared to control mice, oxiracetam-treated DBA mice demonstrated a significant increase in spatial learning performance as determined by the Morris water navigation task. This increase in performance was correlated to an increase in membrane-bound PKC.[7]

The proven effects of the drug are limited to beneficial effects that lead to higher scores in tests for logical performance, attention, concentration, memory and spatial orientation. These tests were performed on patients with mild to moderate dementia and ADHD, and the doses were 800–2400 mg orally twice a day for one to six months. Improvement has also been seen in patients with exogenic post-concussion syndrome, organic brain syndromes and other dementias. According to V. Gallai et al, oxiracetam is more effective than piracetam for this purpose.[6]

[6]

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.